Selegiline

Selegiline

SCHEMBL22232

C#CCN(C)[C@H](C)Cc1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

MAOB

The experimentally established mechanism targets of Selegiline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB known ✓ P27338 11/20 1.00
MAOA P21397 8/20 1.00
CYP1A2 P05177 2/20 1.00
ADRA2B P18089 2/20 1.00
ADRA2C P18825 2/20 1.00
ADRA1A P35348 2/20 1.00
OPRK1 P41145 2/20 1.00
TSHR P16473 2/20 1.00
ADRA2A P08913 1/20 1.00
SNCA P37840 1/20 1.00
CYP2D6 P10635 1/20 1.00
PKM P14618 1/20 1.00
MAPK1 P28482 1/20 0.97
KDM4E B2RXH2 1/20 0.97
SLC6A2 P23975 1/20 0.62
HTR2A P28223 1/20 0.62
SLC6A4 P31645 1/20 0.62
SLC6A3 Q01959 1/20 0.62
KCNH2 Q12809 1/20 0.62
SIGMAR1 Q99720 3/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Selegiline SCHEMBL74753 1.00 MAOB (1.00) MAOBMAOACYP1A2ADRA2BADRA2C
Selegiline SCHEMBL15867136 1.00 MAOB (1.00) MAOBMAOACYP1A2ADRA2BADRA2C
Selegiline SCHEMBL12248117 1.00 MAOB (1.00) MAOBMAOACYP1A2ADRA2BADRA2C
Selegiline SCHEMBL1286950 1.00 MAOB (1.00) MAOBMAOACYP1A2ADRA2BADRA2C
Selegiline SCHEMBL5499736 1.00 MAOB (1.00) MAOBMAOACYP1A2ADRA2BADRA2C
Selegiline SCHEMBL41392 0.98 MAOB (1.00) MAOBMAOACYP1A2ADRA2BADRA2C
Selegiline SCHEMBL473659 0.98 MAOB (1.00) MAOBMAOACYP1A2ADRA2BADRA2C
Selegiline SCHEMBL1171497 0.97 MAOB (0.93) MAOBMAOACYP1A2ADRA2BADRA2C
Selegiline SCHEMBL7105217 0.97 MAOB (0.93) MAOBMAOACYP1A2ADRA2BADRA2C
Selegiline SCHEMBL4611911 0.95 MAOB (0.90) MAOBMAOACYP1A2ADRA2BADRA2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 29740 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3607938-B1 PHARMACEUTICAL COMPOSITION SOVIC BRKICIC LJILJANA (HR) 2026-05-27 EP claimed
WO-2026106939-A1 IMPROVING SYMPTOMS IN MID- TO LATE-STAGE PARKINSON'S DISEASE PATIENTS USING WITH DEEP BRAIN STIMULATION VANDERBILT UNIVERSITY (US) 2026-05-21 WO claimed
US-20260131089-A1 DRUG DELIVERY DEVICES AND METHODS FOR ADMINISTERING SUBSTANCES TO A BODY CAVITY BY HETEROGENOUS AEROSOLIZATION FOR TREATMENT OF BINGE-EATING DISORDERS AND/OR OBESITY APTARGROUP, INC. (US) 2026-05-14 US claimed
US-20260131140-A1 MODIFYING EARLY-STAGE PARKINSON'S DISEASE PROGRESSION WITH DEEP BRAIN STIMULATION VANDERBILT UNIV (US) 2026-05-14 US claimed
EP-4727545-A2 COMBINATION TREATMENTS FOR DEPRESSION AND OTHER DISORDERS Neurawell Therapeutics (US) 2026-04-22 EP claimed
EP-4722714-A1 SIMULTANEOUS ANALYSIS OF FOOD-BORNE DOPING SUBSTANCES USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (VFD: VACCINE FOR FOODBORNE DOPING) Korea Institute of Science and Technology (KR) 2026-04-08 EP claimed
US-12594388-B2 Device to deliver a predetermined amount of a substance to a natural orifice of the body APTARGROUP, INC. (US) 2026-04-07 US claimed
US-20260091047-A1 THERAPEUTIC COMBINATIONS FOR MOVEMENT DISORDERS NATIVE CODE BIO LLC (US) 2026-04-02 US claimed
US-20260092141-A1 SERIES OF POLYMERS HAVING PROPERTIES OF ACID-SENSITIVE DEGRADATION AND TEMPERATURE SENSITIVITY AND DRUG LOADING COMPOSITION THEREOF NANJING FANTAI CHEMICAL PHARMACEUTICAL RESEARCH INSTITUTE (CN) 2026-04-02 US claimed
US-20260076896-A1 CONTINUOUS OR PERIODICAL TRANSDERMAL DELIVERY OF EXOGENOUS MOLECULE KIFFIK BIOMEDICAL INC (US) 2026-03-19 US claimed
US-5057321-A Dosage form comprising drug and maltodextrin ALZA CORPORATION (US) 1991-10-15 US claimed
EP-0413771-A1 COMPOSITION FOR THE TREATMENT OF SCHIZOPHRENIA. CHINOIN GYOGYSZER ES VEGYESZET (HU) 1991-02-27 EP claimed
EP-0406488-A1 A pharmaceutical product for the treatment of Parkinson, Alzheimer and depressive diseases SOMERSET PHARMACEUTICALS, INC. (US) 1991-01-09 EP claimed
EP-0241809-B1 SYNERGISTIC ASSOCIATION OF AMANTADINE AND SELEGILINE ASTA Pharma Aktiengesellschaft (DE) 1990-08-08 EP claimed
WO-1990001928-A1 COMPOSITION FOR THE TREATMENT OF SCHIZOPHRENIA Chinoin Gyógyszer és Vegyészeti Termékek Gyára Rt. (HU) 1990-03-08 WO claimed
US-4868218-A TRANSDERMAL ADMINISTRATION OF DEPRENYL SOMERSET PHARMACEUTICALS, INC., A CORP. OF DELAWARE 1989-09-19 US claimed
US-4861800-A Method for administering the drug deprenyl so as to minimize the danger of side effects SOMERSET PHARMACEUTICALS, INC., A CORP. OF DELAWARE 1989-08-29 US claimed
US-4812481-A Synergistic combination of amantadiene and selegiline DEGUSSA AKTIENGESELLSCHAFT (DE) 1989-03-14 US claimed
CN-86107474-A TOPOLOGIC NETWORK INTELLIGENCE-DEVELOPING TOY SERIES 1988-06-01 CN claimed
EP-0046270-A1 Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them INTERx RESEARCH CORPORATION (US) 1982-02-24 EP claimed